АстраЗенека АБ (SE);Пулмаджин Терапеутикс (Синерджи) Лимитед (GB)
发明人:
АВИТАБИЛ Барбара Джузеппина (GB),НАДИН Алан Джон (GB),РЭЙ Николас Чарлз (GB)
申请号：
RU2011105463/15
公开号：
RU2011105463A
申请日:
2009.08.11
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A pharmaceutical product containing, in combination, a first active ingredient, a muscarinic antagonist, selected from:! (R) -1- [5 - ((R) -cyclohexyl-hydroxy-phenyl-methyl) - [1,3,4] oxadiazol-2-ylmethyl] -3- (4-fluoro-phenoxy) -1-azonia bicyclo [2.2.2] octane X； ! (R) -1- [3 - ((R) -cyclohexyl-hydroxy-phenyl-methyl) -isoxazol-5-ylmethyl] -3- (3-fluoro-phenoxy) -1-azonia-bicyclo [2.2.2] octane X； ! (R) -3- (3-fluoro-4-methyl-phenoxy) -1- [3- (hydroxy-diphenyl-methyl) -isoxazol-5-ylmethyl] -1-azonia-bicyclo [2.2.2] octane X ； ! (R) -3- (3-fluoro-phenylsulfanyl) -1- [3- (hydroxy-diphenyl-methyl) -isoxazol-5-ylmethyl] -1-azonia-bicyclo [2.2.2] octane X； ! (R) -1- [3 - ((R) -cyclohexyl-hydroxy-phenyl-methyl) -isoxazol-5-ylmethyl] -3- (4-fluoro-phenoxy) -1-azonia-bicyclo [2.2.2] octane X； ! where X is a pharmaceutically acceptable anion of a mono- or polyvalent acid, and the second active ingredient is a β2-adrenergic receptor agonist. ! 2. The product according to claim 1, where the first active ingredient is a muscarinic antagonist, which is a bromide salt. ! 3. The product according to claim 1 or 2, where the β2-adrenergic receptor agonist is formoterol. ! 4. The product according to claim 3, where the β2-adrenergic receptor agonist is selected from:! N- [2- (Diethylamino) ethyl] -N- (2 - {[2- (4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl) ethyl] amino} ethyl ) -3- [2- (1-naphthyl) ethoxy] propanamide,! N- [2- (Diethylamino) ethyl] -N- (2 - {[2- (4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl) ethyl] amino} ethyl ) -3- [2- (3-chlorophenyl) ethoxy] propanamide, and! 7 - [(1R) -2 - ({2 - [(34 [2- (2-Chlorophenyl) ethyl] amino} propyl) thio] ethyl} amino) -1-hydroxyethyl] -4-hydroxy-1,3- benzothiazole-2 (3H) -one,! or a pharmaceutically acceptable salt thereof. ! 5. The product according to claim 1 or 2, where the β2-adrenergic receptor agonist is N-cyclohexyl-N3- [2- (3-fluorophenyl) ethyl] -N- (2 - {[2- (4-�1. Фармацевтический продукт, содержащий, в комбина
